Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Apellis Pharmaceuticals Inc APLS

Healthcare Biotechnology
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related... see more

Recent & Breaking News (NDAQ:APLS)

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - APLS

PR Newswire August 4, 2023

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $500,000 to Contact the Firm

Accesswire August 4, 2023

APELLIS PHARMACEUTICALS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. - APLS

Business Wire August 3, 2023

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Newsfile August 3, 2023

Shareholder Alert: Robbins LLP Informs Shareholders of Class Action Filed Against Apellis Pharmaceuticals, Inc. (APLS)

Business Wire August 3, 2023

APLS LAWSUIT ALERT: Levi & Korsinsky Notifies Apellis Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

PR Newswire August 3, 2023

APLS INVESTOR ALERT: KESSLER TOPAZ MELTZER & CHECK, LLP AND BERNSTEIN LITOWITZ BERGER & GROSSMANN LLP ANNOUNCE THE FILING OF A SECURITIES FRAUD CLASS ACTION LAWSUIT AGAINST APELLIS PHARMACEUTICALS, INC. AND ENCOURAGE INVESTORS WITH SUBSTANTIAL LOSSES TO CONTACT THE FIRMS

PR Newswire August 3, 2023

DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Accesswire August 3, 2023

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Newsfile August 2, 2023

APLS Investor Alert: Kessler Topaz Meltzer & Check, LLP and Bernstein Litowitz Berger & Grossmann LLP Announce the Filing of a Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc.

Business Wire August 2, 2023

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Apellis Pharmaceuticals, Inc. and Encourages Investors with Losses In Excess of $250,000 to Contact the Firm

Accesswire August 2, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apellis Pharmaceuticals, Inc. - APLS

Newsfile July 31, 2023

Apellis Investigation Notification: Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) Investors

PR Newswire July 31, 2023

Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results

GlobeNewswire July 31, 2023

SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 30 Months in Patients with Geographic Atrophy (GA)

GlobeNewswire July 30, 2023

Apellis Provides Update on Review of Rare Safety Events with SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy

GlobeNewswire July 29, 2023

APLS Investigation Notice: Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Apellis Pharmaceuticals, Inc. (APLS) Investors

Newsfile July 29, 2023

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Apellis Pharmaceuticals, Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm

Accesswire July 29, 2023

ROSEN, A LEADING AND RANKED FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - APLS

Newsfile July 28, 2023

APLS LOSS ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - APLS

PR Newswire July 27, 2023